• Final data from a first-of-its-kind clinical trial confirm that the combination of Sculptra® and Restylane® Lyft™ or Contour™* delivers sustained improvement in facial aesthetic appearance for patients experiencing facial volume loss due to medication-driven weight loss1
• Following interim analysis at three months presented earlier this year, a six-month extension study was conducted to capture the durability of treatment effects after nine months1
• Galderma continues to lead the response to addressing the aesthetic concerns of patients experiencing medication-driven weight loss, leveraging its deep dermatological expertise and working closely with healthcare professionals to meet evolving patient needs

ZUG, Switzerland -- (BUSINESS WIRE) --

Galderma has revealed positive final data from a phase IV first-of-its-kind trial exploring the benefits of Restylane Lyft or Contour in combination with Sculptra to address the aesthetic concerns of patients experiencing facial volume loss associated with medication-driven weight loss.1 These data reinforce that this treatment regimen can effectively improve facial aesthetic appearance with high patient satisfaction over nine months.1

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250716698427/en/

Rates of medication-driven weight loss have increased rapidly in recent years and can be associated with facial alterations of variable magnitude.2-4 Patients may experience facial changes such as dry, dull or sagging skin, a gaunt or hollowed-out facial appearance, or other unwelcome alterations to facial structure and balance.3,4 As the pure-play dermatology category leader, Galderma is spearheading efforts to identify and address the most predominant aesthetic concerns of patients along their weight loss journey.

"At Galderma, we are leading the charge in redefining aesthetic care for patients impacted by medication-driven weight loss. Our commitment is clear: to empower individuals to reclaim their confidence through cutting-edge, data-driven innovation and strategic collaboration with the world’s foremost experts, and these latest study results reinforce this mission."

FLEMMING ØRNSKOV, M.D., MPH
CHIEF EXECUTIVE OFFICER
GALDERMA

In the phase IV clinical study conducted in the U.S., Galderma investigated the aesthetic outcomes and appearance, and patient satisfaction of Restylane Lyft or Contour in combination with Sculptra for cheek or jawline augmentation and correction of contour deficiencies in patients experiencing facial volume loss associated with medication-driven weight loss.1 The trial used the SHAPE Up Holistic Individualized Treatment (HIT™) – an individualized treatment approach which enables injectors to leverage their expertise with Galderma’s Sculptra and its Restylane portfolio to optimize aesthetic outcomes while prioritizing patient satisfaction.

Patients were treated with Sculptra and either Restylane Lyft or Contour for their first treatment, a second treatment of Sculptra with an optional touch-up of Restylane Lyft or Contour at Week 4, and an optional third treatment of Sculptra at Week 8.1

Following interim analysis at three months presented earlier this year, a six-month extension study was conducted to capture the durability of treatment effects after nine months. In the extension study, follow-up visits took place at Weeks 32 and 44 for those who received the third Sculptra treatment and at Weeks 28 and 40 for those who did not, corresponding to nine months after their first Sculptra treatment.1

Results at nine months demonstrated that the combination of Sculptra and Restylane Lyft or Contour effectively improved the aesthetic appearance of patients experiencing facial volume loss associated with medication-driven weight loss, further supporting the benefits of the SHAPE Up HIT:1

• The combined Sculptra and Restylane Lyft or Contour regimen demonstrated skin quality improvements, with Restylane improving skin hydration and Sculptra significantly improving skin radiance through to Month 91
• Subject satisfaction – which was reported by the majority of patients as early as Week 4 – was maintained through to Month 9:1
  • 85.7% of patients said their face looked less gaunt/sunken1
  • 88.6% said they “loved” how the treatment maintained their facial structure1
  • 88.6% of patients said they “loved” the regenerative effects of Sculptra treatment1
  • 88.6% felt they looked better than before the injection regimen1
  • 91.4% said they would recommend the injection regimen to others after weight loss and to those with loose, sagging facial skin1

Safety was in line with previous pivotal trial data for Sculptra, Restylane Lyft and Contour, with no treatment-related adverse events reports.1

"The improvements we observed with Sculptra and Restylane at nine months are hugely encouraging and represent a meaningful step forward in addressing the most predominant aesthetic concerns of patients along their weight loss journey. It was exciting to see the glow we've clinically observed in the past with Sculptra now validated through innovative bioinstrumentation tools in this study. For physicians and patients who are navigating the visible effects of medication-driven weight loss, this study delivers real, evidence-based solutions that can make a tangible difference to how individuals look and feel."

Z. PAUL LORENC, M.D.
CLINICAL TRIAL INVESTIGATOR
NEW YORK, UNITED STATES

"These results really reinforce the role of aesthetic treatments, like Sculptra and Restylane, in supporting patients through their weight loss transformations, showing they can deliver visible improvements in skin quality while also significantly enhancing patient satisfaction and emotional wellbeing. The findings empower clinicians with data-backed tools to holistically address the nuanced aesthetic needs that arise with medication-driven weight loss, marking a pivotal moment where science meets patient-centered care."

MICHAEL SOMENEK, M.D.
CLINICAL TRIAL INVESTIGATOR
WASHINGTON DC, UNITED STATES

Galderma is spearheading multiple additional initiatives to identify and address the most predominant aesthetic concerns of patients who have experienced medication-driven weight loss through data-driven, innovative approaches in close collaboration with leading healthcare practitioners, as outlined in the company’s recent report.5 Galderma has supported pioneering research in the field, including the first recently published international consensus-based guidelines that provide a practical framework for practitioners to address the aesthetic needs of medication-driven weight loss patients, as well as research into the impact of medication-driven weight loss on the skin and the importance of factoring in aesthetic treatment goals during the patient journey.6

*Restylane Contour is known as Restylane® Volyme™ in countries outside of the U.S.

About the study
This phase IV trial was a multi-center, open-label study to evaluate the synergistic effects of Restylane Lyft or Contour in combination with Sculptra for cheek augmentation and correction of contour deficiencies, in patients experiencing facial volume loss following treatment with one of four brands of glucagon-like peptide-1 (GLP-1) receptor agonists.1 Conducted in the U.S., the trial took place across two sites, and used the SHAPE Up Holistic Individualized Treatment (HIT) as a treatment methodology, with patients treated with Sculptra and either Restylane Lyft or Contour for their first treatment, a second treatment of Sculptra with an optional touch-up of Restylane Lyft or Contour at Week 4, and an optional third treatment of Sculptra at Week 8.1

About Galderma
Galderma (SIX: GALD) is the pure-play dermatology category leader, present in approximately 90 countries. We deliver an innovative, science-based portfolio of premium flagship brands and services that span the full spectrum of the fast-growing dermatology market through Injectable Aesthetics, Dermatological Skincare and Therapeutic Dermatology. Since our foundation in 1981, we have dedicated our focus and passion to the human body’s largest organ – the skin – meeting individual consumer and patient needs with superior outcomes in partnership with healthcare professionals. Because we understand that the skin we are in shapes our lives, we are advancing dermatology for every skin story. For more information: www.galderma.com.

References

1. Galderma. Data on file. Somenek M and Lorenc P. A multi-center, open-label study to evaluate the synergistic effects of biostimulator and dermal fillers for cheek augmentation and correction of contour deficiencies: Nine-month topline results.
2. Mansour MR, et al. The rise of “Ozempic Face”: Analyzing trends and treatment challenges associated with rapid facial weight loss induced by GLP-1 agonists. JPRAS. 2024;96:225-227. doi: 10.1016/j.bjps.2024.07.051
3. Tay JQ. Ozempic face: A new challenge for facial plastic surgeons. JPRAS. 2023;81:97-98. doi: 10.1016/j.bjps.2023.04.057
4. Humphrey CD and Lawrence AC. Implications of Ozempic and other GLP-1 receptor agonists for facial plastic surgeons. Facial Plast Surg. 2023;39:719-721. doi: 10.1055/a-2148-6321
5. Galderma. Balancing The Scales: Advancing Aesthetics In The Era Of Medication-driven Weight Loss Transformations. July 2025. Available online
6. Nikolis A, et al. Consensus Statements on Managing Aesthetic Needs in Prescription Medication-Driven Weight Loss Patients: An International, Multidisciplinary Delphi Study. JCD. 2025;24: e70094. https://doi.org/10.1111/jocd.70094